485 related articles for article (PubMed ID: 11488999)
1. The integration of paclitaxel and new platinum compounds in the treatment of advanced ovarian cancer.
Vermorken JB
Int J Gynecol Cancer; 2001; 11 Suppl 1():21-30. PubMed ID: 11488999
[TBL] [Abstract][Full Text] [Related]
2. A systematic overview of chemotherapy effects in ovarian cancer.
Högberg T; Glimelius B; Nygren P;
Acta Oncol; 2001; 40(2-3):340-60. PubMed ID: 11441940
[TBL] [Abstract][Full Text] [Related]
3. Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: A randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group.
Piccart MJ; Green JA; Lacave AJ; Reed N; Vergote I; Benedetti-Panici P; Bonetti A; Kristeller-Tome V; Fernandez CM; Curran D; Van Glabbeke M; Lacombe D; Pinel MC; Pecorelli S
J Clin Oncol; 2000 Mar; 18(6):1193-202. PubMed ID: 10715288
[TBL] [Abstract][Full Text] [Related]
4. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
5. Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group.
du Bois A; Lück HJ; Meier W; Möbus V; Costa S; Richter B; Warm M; Bauknecht T; Schröder W; Olbricht S; Nitz U; Jackisch C
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-44-S15-52. PubMed ID: 9346222
[TBL] [Abstract][Full Text] [Related]
6. Taxanes as first-line therapy for advanced non-small cell lung cancer: a systematic review and practice guideline.
Chu Q; Vincent M; Logan D; Mackay JA; Evans WK;
Lung Cancer; 2005 Dec; 50(3):355-74. PubMed ID: 16139391
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study.
Pujade-Lauraine E; Guastalla JP; Weber B; Curé H; Orfeuvre H; Mousseau M; Vincent P; Diéras V; Tubiana-Mathieu N; Jacquin JP; Mignot L; Leduc B; Paraïso D; Viens P
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-30-S15-35. PubMed ID: 9346219
[TBL] [Abstract][Full Text] [Related]
8. ICON 2 and ICON 3 data in previously untreated ovarian cancer: results to date.
Harper P
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-23-S15-25. PubMed ID: 9346217
[TBL] [Abstract][Full Text] [Related]
9. Platinum compounds in the treatment of advanced breast cancer.
Martín M
Clin Breast Cancer; 2001 Oct; 2(3):190-208; discussion 209. PubMed ID: 11899413
[TBL] [Abstract][Full Text] [Related]
10. Carboplatin versus cisplatin in ovarian cancer.
Alberts DS
Semin Oncol; 1995 Oct; 22(5 Suppl 12):88-90. PubMed ID: 7481869
[TBL] [Abstract][Full Text] [Related]
11. Systematic review of first-line chemotherapy for newly diagnosed postoperative patients with stage II, III, or IV epithelial ovarian cancer.
Covens A; Carey M; Bryson P; Verma S; Fung Kee Fung M; Johnston M
Gynecol Oncol; 2002 Apr; 85(1):71-80. PubMed ID: 11925123
[TBL] [Abstract][Full Text] [Related]
12. Advanced ovarian cancer: a clinical update on first-line treatment, recurrent disease, and new agents.
Ozols RF
J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S60-73. PubMed ID: 19780247
[TBL] [Abstract][Full Text] [Related]
13. Long-term results of a randomised phase III trial of weekly versus three-weekly paclitaxel/platinum induction therapy followed by standard or extended three-weekly paclitaxel/platinum in European patients with advanced epithelial ovarian cancer.
van der Burg ME; Onstenk W; Boere IA; Look M; Ottevanger PB; de Gooyer D; Kerkhofs LG; Valster FA; Ruit JB; van Reisen AG; Goey SH; van der Torren AM; ten Bokkel Huinink D; Kok TC; Verweij J; van Doorn HC
Eur J Cancer; 2014 Oct; 50(15):2592-601. PubMed ID: 25096168
[TBL] [Abstract][Full Text] [Related]
14. [Docetaxel and ovarian cancer].
Ray-Coquard I
Bull Cancer; 2004 Feb; 91(2):159-65. PubMed ID: 15047455
[TBL] [Abstract][Full Text] [Related]
15. Docetaxel: an alternative taxane in ovarian cancer.
Katsumata N
Br J Cancer; 2003 Dec; 89 Suppl 3(Suppl 3):S9-S15. PubMed ID: 14661041
[TBL] [Abstract][Full Text] [Related]
16. Paclitaxel with carboplatin versus paclitaxel with carboplatin alternating with cisplatin as first-line chemotherapy in advanced epithelial ovarian cancer: preliminary results of a Hellenic Cooperative Oncology Group study.
Skarlos DV; Aravantinos G; Kosmidis P; Athanassiadis A; Stathopoulos GP; Pavlidis N; Bafaloukos D; Karphathios S; Papakostas P; Bamia C; Fountzilas G
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-57-S15-61. PubMed ID: 9346224
[TBL] [Abstract][Full Text] [Related]
17. The taxoids. Comparative clinical pharmacology and therapeutic potential.
Eisenhauer EA; Vermorken JB
Drugs; 1998 Jan; 55(1):5-30. PubMed ID: 9463787
[TBL] [Abstract][Full Text] [Related]
18. Paclitaxel: a pharmacoeconomic review of its use in the treatment of ovarian cancer.
Young M; Plosker GL
Pharmacoeconomics; 2001; 19(12):1227-59. PubMed ID: 11772158
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of the paclitaxel and carboplatin combination in patients with previously treated advanced ovarian carcinoma. A multicenter GINECO (Group d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens) phase II study.
Guastalla JP; Pujade-Lauraine E; Weber B; Cuŕe H; Orfeuvre H; Mousseau M; Vincent P; Diéras V; Tubiana-Mathieu N; Jacquin JP; Mignot L; Leduc B; Viens P; Pariso D
Ann Oncol; 1998 Jan; 9(1):37-43. PubMed ID: 9541681
[TBL] [Abstract][Full Text] [Related]
20. Platinum compounds and paclitaxel in advanced epithelial ovarian cancer.
Gadducci A; Brunetti I; Cosio S; Giannessi PG; Genazzani AR; Conte P
Anticancer Res; 1997; 17(6D):4703-8. PubMed ID: 9494592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]